BICYCLE THERAPEUTICS PLC (BCYC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BCYC currently has 50.4M outstanding shares. with significant dilution risk as 74.6M authorized shares could dilute existing holders by 148.1%. The company has significantly diluted shareholders by 107.31% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 30, 2026 |
10-Q filing | 50.4M shares outstanding |
50M | 75M |
| Mar 17, 2026 |
10-K filing | 49.9M shares outstanding |
50M | 75M |
| Aug 08, 2025 |
S-3 filing: The filing is an S-3 registration statement to register Ordinary Shares, American Depositary Shares representing Ordinary Shares, Preference Shares, Debt Securities, Warrants, Rights, Units up to $500,000,000 and ADSs offered by selling securityholders. |
69M | 56M |
| Aug 08, 2025 |
10-Q filing | 49.9M shares outstanding |
50M | 0 |
| May 01, 2025 |
10-Q filing | 69.2M shares outstanding |
69M | 0 |
| Feb 25, 2025 |
10-K filing | 47.6M shares outstanding |
48M | 0 |
| Oct 31, 2024 |
10-Q filing | 47.6M shares outstanding |
48M | 0 |
| Aug 06, 2024 |
10-Q filing | 52.0M shares outstanding |
52M | 0 |
| Jun 18, 2024 |
8-K filing: Bicycle Therapeutics plc filed a prospectus supplement related to the resale of up to 37,656,764 ordinary shares by selling securityholders. |
43M | 0 |
| May 23, 2024 |
8-K filing: Bicycle Therapeutics plc entered into a securities purchase agreement to sell 25,933,706 American Depositary Shares or non-voting ordinary shares at $21.42 per share, with aggregate gross proceeds of approximately $555 million before deducting fees and expenses. ($555.0M proceeds) |
43M | 0 |
| May 02, 2024 |
10-Q filing | 42.6M shares outstanding |
43M | 0 |
| Feb 20, 2024 |
10-K filing | 42.4M shares outstanding |
42M | 0 |
| Nov 02, 2023 |
10-Q filing | 39.6M shares outstanding |
40M | 0 |
| Aug 03, 2023 |
10-Q filing | 30.2M shares outstanding |
30M | 2.4M |
| Jul 13, 2023 |
8-K filing: Bicycle Therapeutics plc entered into an underwriting agreement to issue and sell 9,411,766 American Depositary Shares (ADSs) and non-voting ordinary shares at a public offering price of $21.25 per share, with net proceeds expected to be approximately $187.3 million. ($187.3M proceeds) |
30M | 2.5M |
| May 04, 2023 |
10-Q filing | 30.0M shares outstanding |
30M | 2.5M |
| Feb 28, 2023 |
10-K filing | 29.7M shares outstanding |
30M | 2.9M |
| Nov 03, 2022 |
10-Q filing | 29.7M shares outstanding |
30M | 2.9M |
| Aug 04, 2022 |
10-Q filing | 29.6M shares outstanding |
30M | 2.9M |
| May 05, 2022 |
10-Q filing | 29.6M shares outstanding |
30M | 2.9M |
| Mar 01, 2022 |
10-K filing | 29.6M shares outstanding |
30M | 3M |
| Nov 04, 2021 |
10-Q filing | 25.0M shares outstanding |
25M | 7.5M |
| Oct 14, 2021 |
8-K filing: Bicycle Therapeutics plc entered into an underwriting agreement to issue and sell 3,240,741 American Depositary Shares at a public offering price of $54.00 per ADS, with net proceeds expected to be approximately $163.8 million. An option for the Underwriters to purchase 486,111 additional ADSs also exists. ($175.0M proceeds) |
24M | 8.5M |
| Aug 05, 2021 |
10-Q filing | 24.1M shares outstanding |
24M | 8.5M |
| May 06, 2021 |
10-Q filing | 24.1M shares outstanding |
24M | 8.5M |
| Mar 11, 2021 |
10-K filing | 23.1M shares outstanding |
23M | 9.5M |
| Nov 05, 2020 |
10-Q filing | 21.3M shares outstanding |
21M | 11M |
| Aug 05, 2020 |
10-Q filing | 19.3M shares outstanding |
19M | 13M |
| Jun 05, 2020 |
S-3 filing: The filing is for a shelf registration to issue up to $250,000,000 of any combination of ordinary shares, American Depositary Shares, preference shares, debt securities, warrants, rights, or units. |
18M | 14M |
| May 07, 2020 |
10-Q filing | 18.1M shares outstanding |
18M | 0 |
| Mar 10, 2020 |
10-K filing | 18.0M shares outstanding |
18M | 0 |